R&D













The days of biotech and pharma basic research are gone. It is all about commercializing compounds from smaller takeover candidates that have phase 1 data. The companies are in the business of bringing a known biologic or compound to market. The bigger companies would rather acquire something than try to do it in house.
 












The days of biotech and pharma basic research are gone. It is all about commercializing compounds from smaller takeover candidates that have phase 1 data. The companies are in the business of bringing a known biologic or compound to market. The bigger companies would rather acquire something than try to do it in house.

...and the funny part of this model as it relates to Amgen is the complete history of failures tinkering with this model for several years. They have tried and failed repeatedly (and expensively $$$).....oh, but it will be different from here forward without all these pesky accomplished scientists standing in the way.....not!!